Sriram Krishnaswami
Overview
Explore the profile of Sriram Krishnaswami including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
3320
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jayachandran P, Desikan R, Krishnaswami S, Hennig S
CPT Pharmacometrics Syst Pharmacol
. 2023 Oct;
12(11):1569-1572.
PMID: 37849052
No abstract available.
2.
Rowland Yeo K, Hennig S, Krishnaswami S, Strydom N, Ayyar V, French J, et al.
CPT Pharmacometrics Syst Pharmacol
. 2021 Jul;
10(7):649-657.
PMID: 34298582
No abstract available.
3.
Tse S, Dowty M, Menon S, Gupta P, Krishnaswami S
J Clin Pharmacol
. 2020 Jun;
60(12):1617-1628.
PMID: 32592424
Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. It is eliminated via multiple pathways including oxidative metabolism (∼70%) and renal...
4.
Krishnaswami S, Austin D, Della Pasqua O, Gastonguay M, Gobburu J, van der Graaf P, et al.
Clin Pharmacol Ther
. 2020 Jan;
107(4):762-772.
PMID: 31955417
No abstract available.
5.
Venkatakrishnan K, Zheng S, Musante C, Jin J, Riggs M, Krishnaswami S, et al.
Clin Pharmacol Ther
. 2019 Nov;
107(1):85-88.
PMID: 31750932
Quantitative translational medicine (QTM) is envisioned as a multifaceted discipline that will galvanize the path from idea to medicine through quantitative translation across the discovery, development, regulatory, and utilization spectrum....
6.
Miyoshi S, Krishnaswami S, Toyoizumi S, Nakamura H, Zwillich S
Clin Pharmacol Drug Dev
. 2019 Nov;
9(1):11-20.
PMID: 31713350
The aim of the study was to characterize the pharmacokinetics, safety, and tolerability of tofacitinib, an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis, psoriatic arthritis, and ulcerative...
7.
Suzuki M, Shoji S, Miyoshi S, Krishnaswami S
J Clin Pharmacol
. 2019 Sep;
60(2):198-208.
PMID: 31512746
Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). The aim of this analysis was to characterize the relationship between tofacitinib dose and efficacy, as...
8.
van Vollenhoven R, Lee E, Strengholt S, Mojcik C, Valdez H, Krishnaswami S, et al.
Arthritis Rheumatol
. 2018 Nov;
71(5):685-695.
PMID: 30427585
Objective: Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). Altered lymphocyte cell counts and a potential association with increased infection rates have been reported in...
9.
Ma G, Xie R, Strober B, Langley R, Ito K, Krishnaswami S, et al.
Clin Pharmacol Drug Dev
. 2018 Jun;
7(6):587-596.
PMID: 29856518
Tofacitinib is an oral Janus kinase (JAK) inhibitor. This study characterized the pharmacokinetics of tofacitinib in patients with psoriasis and evaluated the impact of patient factors on disposition. Pooled phase...
10.
Ruperto N, Brunner H, Zuber Z, Tzaribachev N, Kingsbury D, Foeldvari I, et al.
Pediatr Rheumatol Online J
. 2017 Dec;
15(1):86.
PMID: 29282090
Background: Juvenile idiopathic arthritis (JIA) is the most common pediatric rheumatic disease and a leading cause of childhood disability. The objective of this study was to characterize the PK, safety,...